Antigen Dynamics in Melanocytic and Nevocytic Melanoma Oncogenesis: Anti-Ganglioside and Anti-ras p21 Antibodies as Markers of Tumor Progression
- 1 February 1990
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 94 (2) , 174-182
- https://doi.org/10.1111/1523-1747.ep12874447
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Tumor progression in human malignant melanoma: Five stages defined by their antigenic phenotypesInternational Journal of Cancer, 1987
- Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells.The Journal of Experimental Medicine, 1987
- Immunohistochemical detection of antigen in human primary and metastatic melanomas by the monoclonal antibody 140.240 and its possible prognostic significanceCancer, 1987
- Human Monoclonal Antibodies That Distinguish Cutaneous Malignant Melanomas from Benign Nevi in Fixed Tissue SectionsJournal of Investigative Dermatology, 1986
- Phenotypic dynamics of tumor progression in human malignant melanomaInternational Journal of Cancer, 1985
- Monoclonal Antibodies Selected to Discriminate Between Malignant Melanomas and Nevocellular NeviJournal of Investigative Dermatology, 1985
- In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. Differential expression of two surface molecules, gp75 and p89.The Journal of Experimental Medicine, 1985
- Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.Proceedings of the National Academy of Sciences, 1980
- Melanocytic and nevocytic malignant melanomas.Cellular and subcellular differentiationCancer, 1967
- Macromolecular Changes in Pigmentary DisordersArchives of Dermatology, 1965